🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The FDA has approved nivolumab + ipilimumab for patients with unresectable or metastatic #HCC 👏 fda.gov/drugs/resource…

Exciting new approach for FGFR2 driven cancers! jci.org/articles/view/…

Identification of potent biparatopic antibodies targeting FGFR2 fusion–driven cholangiocarcinoma Journal of Clinical Investigation 👉targeting the FGFR2 extracellular domain 👉synergy with FGFR inhibitors & activity against kinase domain mutations 🧐Exciting to see evolving options in BTC

Nakazawa et al. studied the peripheral immune profile of a cohort of patients with advanced solid tumors; 54 patients received anti-PD-(L)1 alone and 50 received anti-PD-(L)1 + anti-CTLA-4. bit.ly/42qWx4d  Johns Hopkins University Mari Nakazawa  Mark Yarchoan

1/ Excited to share our study (rdcu.be/eiAyr) published today in Nature Communications led by Chester Kao, Soren Charmsaz, and Hua-Ling Tsai evaluating age-related differences in immune responses in patients with cancer treated with immune checkpoint inhibitors (ICIs).

Older adults respond well to anti-PD1 despite age-related immune differences, Daniel Zabransky Findings may not extend to therapeutic cancer vaccines, which likely require naive T cells Summary of findings below⏬ 🔗 nature.com/articles/s4146…

NEW content online! Recent advances in therapeutic cancer vaccines bit.ly/4k1eXyK

Review Nature Reviews Cancer Recent advances in therapeutic cancer vaccines Dr. Neeha Zaidi Mark Yarchoan Dr. Elizabeth Jaffee nature.com/articles/s4156…

"An opportunity for Trump: Position U.S. cancer science to lead the world," writes Wafik S. El-Deiry, MD, PhD, FACP (Legorreta Cancer Center at Brown University) cancerletter.com/guest-editoria…

I was not aware that Cancer (NCI) was such a small - and decreasing - percentage of the NIH budget cancerletter.com/guest-editoria…

What is your preferred second-line therapy for most patients with HCC who have progressed on first-line atezolizumab plus bevacizumab?

The future of medical oncology is brighter than ever #ASCO2025 Marina Baretti Kristen A. Marrone, MD Kai-li Liang Phaedon Zavras

🩺🧬 SURF Trial: Surgery vs RFA in Small HCC (≤3cm, ≤3 nodules) 📊 Randomized trial (n=302) & observational cohort (n=753) in Japan: •⚔️ 5-yr OS: Surgery 74.6% vs RFA 70.4% (HR 0.96, P=0.84) •🔄 5-yr RFS: Surgery 42.9% vs RFA 42.7% (HR 0.90, P=0.84) •🩹 Serious AEs: 3.3%

cbsnews.com/news/when-is-c…

New #JITC position article and guidelines: SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy bit.ly/4nqheW3 Robert Ferris, MD, PhD MarleenKokLab Evan Lipson Marco Ruella Mark Yarchoan